Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $65,325.48 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 3,993 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the completion of the transaction, the director now owns 3,707,420 shares in the company, valued at $60,653,391.20. This trade represents a 0.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Tyra Biosciences Stock Performance

NASDAQ TYRA opened at $16.24 on Friday. Tyra Biosciences, Inc. has a 52 week low of $12.34 and a 52 week high of $29.60. The business has a 50 day moving average price of $15.38 and a 200-day moving average price of $19.17.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). Equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. UBS Group assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Monday, January 13th. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, Wedbush restated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $30.50.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in TYRA. HighVista Strategies LLC acquired a new position in Tyra Biosciences during the 2nd quarter valued at about $257,000. Franklin Resources Inc. purchased a new position in shares of Tyra Biosciences during the third quarter valued at approximately $278,000. Valence8 US LP bought a new stake in Tyra Biosciences during the third quarter worth $310,000. SG Americas Securities LLC purchased a new stake in Tyra Biosciences in the 3rd quarter valued at $311,000. Finally, The Manufacturers Life Insurance Company bought a new position in Tyra Biosciences during the 3rd quarter valued at $333,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.